Parabilis Medicines Upsized IPO Priced

Parabilis Medicines, a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 33,500,000 shares of common stock at $20.00 per share, aiming to raise $670 million. The company also granted underwriters a 30-day option to purchase an additional 5,025,000 shares. Concurrently, Parabilis Medicines agreed to sell 4,166,666 shares at $18.00 per share to Regeneron Pharmaceuticals, Inc. in a private placement, expecting to receive approximately $75 million. The common stock is anticipated to begin trading on the Nasdaq-100 Global Select Market on June 10, 2026, under the ticker symbol 'PBLS'. Leerink Partners, Meritz Securities, Evercore, and Guggenheim Partners are acting as active book-running managers, with LifeSci Capital LLC as a passive bookrunning manager. Registration statements for the offering became effective with the United States — United States Securities and Exchange Commission on June 9, 2026.